Emergent Biosolutions, Inc.【EBS】 業績推移・財務諸表

(単位:千ドル) 2Q11 3Q11 1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 1Q22 2Q22 3Q22 1Q23 2Q23 3Q23 1Q24 2Q24 3Q24 1Q25
売上高 88,141 58,762 50,311 70,379 66,592 94,606 43,100 82,436 89,102 98,107 53,884 110,325 137,954 63,633 126,112 164,940 168,104 111,002 101,487 142,914 151,663 116,858 100,772 149,434 193,809 117,814 220,200 173,653 270,700 190,600 243,200 311,800 360,400 192,500 394,700 385,200 583,000 343,000 397,500 329,000 307,500 242,700 240,000 165,100 337,900 270,500 300,400 254,700 293,800 222,200
売上成長率(%) - - - - -
売上原価 16,069 10,706 7,511 13,186 10,230 - 5,698 16,945 20,063 - 18,997 34,507 32,423 18,748 27,266 38,511 - 28,503 35,612 39,560 - 46,322 34,624 44,503 - 58,044 89,173 73,232 - 91,800 100,800 108,000 - 76,900 129,800 149,000 - 99,300 227,800 - - - - 155,100 190,600 176,800 144,600 296,100 122,600 88,500
研究開発費 31,481 29,216 26,246 30,645 27,390 - 30,724 30,278 28,937 - 30,256 37,401 44,207 38,702 40,941 41,868 - 34,154 35,347 27,188 - 20,476 25,751 22,659 - 29,051 24,745 37,006 - 46,100 63,900 53,400 - 42,700 47,900 84,400 - 52,500 48,900 49,600 46,400 49,800 39,200 40,600 26,000 15,300 15,100 32,700 13,800 15,100
販売管理費 20,384 17,432 19,492 17,895 19,155 - 20,028 20,501 21,955 - 30,089 30,555 30,292 34,493 36,453 31,556 - 39,784 44,148 40,688 - 35,150 31,868 34,503 - 40,204 39,506 42,105 - 65,400 70,800 65,000 - 69,700 76,000 75,500 - 80,900 91,200 82,100 84,800 81,100 80,200 100,500 91,400 86,000 84,700 85,900 76,600 52,400
営業費用 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 217,800 250,200 241,100 - - - - - - - - - - - - - - - - - -
営業利益 20,207 1,408 -12,538 8,653 9,817 24,035 -13,350 14,712 18,147 23,293 -25,458 7,862 31,032 -28,310 21,452 53,005 49,892 8,561 -13,620 35,478 - 14,910 8,529 47,769 - -9,485 66,776 21,310 - -27,200 -7,000 70,700 - -11,600 126,000 61,300 258,100 95,400 14,500 -34,700 6,400 -72,000 -42,000 -148,100 -292,900 -242,100 39,800 -203,500 64,500 49,900
営業利益率 (%) - - - -
経常(税引前)利益 20,186 1,467 -11,662 9,589 9,856 - -13,321 14,737 18,293 - -28,441 7,494 29,701 -29,789 19,600 52,076 - 7,339 -14,892 33,553 - 13,645 6,721 46,314 - -9,423 65,821 21,559 - -37,800 -15,100 58,900 - -21,300 120,700 55,000 - 85,200 7,200 -45,500 -3,800 -82,800 -63,900 -161,100 -250,200 -265,900 12,100 -269,800 142,400 92,700
経常(税引前)利益率(%) 22.9 2.5 -23.18 13.62 14.8 - -30.91 17.88 20.53 - -52.78 6.79 21.53 -46.81 15.54 31.57 - 6.61 -14.67 23.48 - 11.68 6.67 30.99 - -8.0 29.89 12.41 - -19.83 -6.21 18.89 - -11.06 30.58 14.28 - 24.84 1.81 -13.83 -1.24 -34.12 -26.63 -97.58 -74.05 -98.3 4.03 -105.93 48.47 41.72
法人税等合計 7,663 1,604 -3,640 4,043 4,236 - -4,516 4,381 4,802 - -8,205 2,465 7,869 -8,269 5,500 15,134 - 3,348 -3,945 13,165 - 3,160 2,105 12,763 - -4,515 15,677 614 - -11,800 -5,600 15,700 - -8,800 28,000 15,500 - 15,500 2,600 -12,800 -100 -26,400 11,800 21,900 11,100 -2,500 3,100 13,300 27,600 24,700
実効税率(%) - - - - - - - -
純利益 14,210 1,549 -6,829 7,632 6,617 16,104 -8,062 10,484 13,491 15,222 -20,236 5,029 21,832 -21,520 14,100 36,942 33,347 3,991 -10,947 21,340 37,392 10,485 4,616 33,551 - -4,908 50,144 20,945 - -26,000 -9,500 43,200 46,900 -12,500 92,700 39,500 185,400 69,700 4,600 -32,700 -3,700 -56,400 -75,700 -183,000 -261,300 -263,400 9,000 -283,100 114,800 68,000
純利益率(%) - -
一株あたり利益 0.4 0.04 -0.19 0.21 0.18 0.45 -0.22 0.29 0.37 0.42 -0.55 0.13 0.58 -0.57 0.37 0.95 0.85 0.1 -0.27 0.52 0.93 0.26 0.11 0.81 - -0.1 1 0.42 - -0.51 -0.18 0.84 0.91 -0.24 1.76 0.75 3.51 1.31 0.09 -0.61 -0.07 -1.13 -1.52 -3.65 -5.15 -5.08 0.17 -5.38 2.16 1.25
希薄化後一株あたり利益 0.39 0.04 -0.19 0.21 0.18 0.44 -0.22 0.29 0.36 0.41 -0.55 0.13 0.49 -0.57 0.32 0.79 0.71 0.1 -0.27 0.45 0.77 0.23 0.11 0.68 - -0.1 0.98 0.41 - -0.51 -0.18 0.83 0.9 -0.24 1.73 0.73 3.44 1.28 0.09 -0.61 -0.07 -1.13 -1.52 -3.65 -5.15 -5.08 0.17 -5.38 2.06 1.19
EBITDA - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
EBITDAマージン(%) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -